Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Barr Generic Tambocor Launch Planned For Fall Following Win In Patent Case

Executive Summary

Barr is planning to launch a generic version of 3M's Tambocor (flecainide) in the fall following a favorable court decision in a patent infringement case.

You may also be interested in...



Generic Success In Patent Cases May Slow Momentum For Waxman/Hatch Fix

A string of recent patent victories for the generic industry may take some momentum away from the drive for Waxman/Hatch reform

Generic Success In Patent Cases May Slow Momentum For Waxman/Hatch Fix

A string of recent patent victories for the generic industry may take some momentum away from the drive for Waxman/Hatch reform

Tambocor Dispute, FTC Report May Keep Generic Drugs On Congress' Agenda

A dispute between Par and Barr over generic exclusivity for flecainide reflects the continued complexities in the Waxman/Hatch process that could drive Congressional action over the next 18 months.

Related Content

UsernamePublicRestriction

Register

PS037818

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel